Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation.
Division of Transplantation, University of Miami School of Medicine, Miami, Florida, USA.
S
S
Nishida
A
A
Pinna
R
R
Verzaro
D
D
Levi
T
T
Kato
F
F
Khan
J
J
Nery
D
D
Weppler
A
A
Tzakis
D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000627:therapeutic use*
D015415:Biomarkers; D007166:Immunosuppressive Agents; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin; D020123:Sirolimus